Document resource
As respiratory paediatricians, we were disappointed to see the negative results reported previously in the AZTEC trial1 as we have found it to be a useful treatment in a range of lung diseases affecting children. Although the effects are modest, there is compelling evidence to show azithromycin is useful in cystic fibrosis,2 3 primary ciliary dyskinesia4 and severe asthma.5 Despite a paucity of evidence, it is also widely used in children with protracted bacterial bronchitis6 as well as in those with bronchiolitis obliterans7 and interstitial lung disease.8